180 Life Sciences Corp. (ATNF): Price and Financial Metrics

180 Life Sciences Corp. (ATNF): $1.58

0.07 (-4.24%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ATNF to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#201 of 362

in industry

ATNF Price/Volume Stats

Current price $1.58 52-week high $27.93
Prev. close $1.65 52-week low $1.33
Day low $1.48 Volume 50,000
Day high $1.67 Avg. volume 94,008
50-day MA $2.33 Dividend yield N/A
200-day MA $6.23 Market Cap 1.35M

ATNF Stock Price Chart Interactive Chart >


180 Life Sciences Corp. (ATNF) Company Bio


180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.


ATNF Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNF Latest Social Stream


Loading social stream, please wait...

View Full ATNF Social Stream

Latest ATNF News From Around the Web

Below are the latest news stories about 180 LIFE SCIENCES CORP that investors may wish to consider to help them evaluate ATNF as an investment opportunity.

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination,

Yahoo | December 4, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

William White on InvestorPlace | November 29, 2023

180 Life Sciences Announces Review of Strategic Alternatives

PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options. Ther

Yahoo | November 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | October 19, 2023

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately e

Yahoo | August 14, 2023

Read More 'ATNF' Stories Here

ATNF Price Returns

1-mo -13.66%
3-mo -59.49%
6-mo -77.46%
1-year -93.35%
3-year -99.94%
5-year N/A
YTD -61.05%
2023 -93.70%
2022 -95.65%
2021 42.86%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!